Design, synthesis, and biological evaluation of novel substituted benzamide derivatives bearing a 1,2,3-triazole moiety as potent human dihydroorotate dehydrogenase inhibitors
- PMID: 29316525
- DOI: 10.1016/j.bioorg.2017.12.025
Design, synthesis, and biological evaluation of novel substituted benzamide derivatives bearing a 1,2,3-triazole moiety as potent human dihydroorotate dehydrogenase inhibitors
Abstract
A novel series of substituted benzamide derivatives bearing a 1,2,3-triazole moiety were designed and synthesized by click chemistry. Human dihydroorotate dehydrogenase inhibition assay was used to evaluate the synthesized compounds as potent hDHODH inhibitors. Most compounds showed moderate to significant potency, accompanied with a suitable clogD7.4 value and compounds 4d, 4o, and 5j effectively inhibited the activity of hDHODH with IC50 values of 2.1, 2.1 and 1.5 μM, respectively. Compound 4o also effectively suppressed proliferation of the activated PBMCs. The study of structure-activity relationships also revealed that a suitable substitution on para-position of terminal phenyl ring was crucial for high activity. Together, the most promising compound 4o might serve as a novel hDHODH inhibitors for further investigation.
Keywords: 1,2,3-Triazole; Bioisosterism; Human dihydroorotate dehydrogenase (hDHODH) inhibitors; Immunosuppressive activity; Scaffold-hopping.
Copyright © 2017. Published by Elsevier Inc.
Similar articles
-
Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds.Eur J Med Chem. 2017 Mar 31;129:287-302. doi: 10.1016/j.ejmech.2017.02.017. Epub 2017 Feb 14. Eur J Med Chem. 2017. PMID: 28235702
-
Discovery of a novel series of hDHODH inhibitors with anti-pulmonary fibrotic activities.Bioorg Chem. 2019 May;86:44-51. doi: 10.1016/j.bioorg.2019.01.011. Epub 2019 Jan 7. Bioorg Chem. 2019. PMID: 30685643
-
Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents.Eur J Med Chem. 2014 Jul 23;82:385-93. doi: 10.1016/j.ejmech.2014.05.064. Epub 2014 May 27. Eur J Med Chem. 2014. PMID: 24929289
-
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.Recent Pat Anticancer Drug Discov. 2018;13(1):86-105. doi: 10.2174/1574892812666171108124218. Recent Pat Anticancer Drug Discov. 2018. PMID: 29119937 Review.
-
Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.Eur J Med Chem. 2022 Mar 15;232:114176. doi: 10.1016/j.ejmech.2022.114176. Epub 2022 Feb 3. Eur J Med Chem. 2022. PMID: 35151222 Review.
Cited by
-
Fluorinated triazoles as privileged potential candidates in drug development-focusing on their biological and pharmaceutical properties.Front Chem. 2022 Aug 9;10:926723. doi: 10.3389/fchem.2022.926723. eCollection 2022. Front Chem. 2022. PMID: 36017163 Free PMC article. Review.
-
1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview.Bioorg Med Chem. 2019 Aug 15;27(16):3511-3531. doi: 10.1016/j.bmc.2019.07.005. Epub 2019 Jul 4. Bioorg Med Chem. 2019. PMID: 31300317 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
